Gallup poll shows Obama most admired living man for 6th year in a row
and Hillary Clinton, our next president, the most admired living woman.
What is it about the Republican party that admired people into the Democratic party?
That is the question FoxNews needs to address!
""FDA is aware that if Vascepa's labeling is not revised to reflect the Anchor trial we will not continue Reduce-It in its current form"
I guess we'll now see if the FDA is willing to call Amarin on this.
It's hard to see how the FDA could prevent Amarin amending the label to include Anchor results without violating Amarin's first amendment rights to free speech. Incredible it has to come to this.
Mike W. Hunkapiller, PhD Transactions
Date Shares Transaction Value
12/11/2013 55,087 Acquisition at $4.16 per share. 229,161
12/11/2013 44,913 Acquisition at $4.1 per share. 184,143
11/21/2013 200,000 Acquisition at $3.61 per share. 722,000
11/30/2012 56,700 Acquisition at $1.75 per share. 99,225
11/30/2012 97,400 Acquisition at $1.76 per share. 171,424
11/27/2012 97,400 Acquisition at $1.74 per share. 169,476
11/27/2012 97,400 Acquisition at $1.68 per share. 163,632
11/27/2012 47,400 Acquisition at $1.55 per share. 73,470
11/21/2012 97,400 Acquisition at $1.49 per share. 145,126
11/21/2012 50,000 Acquisition at $1.45 per share. 72,500
11/21/2012 39,000 Acquisition at $1.32 per share. 51,480
11/19/2012 65,600 Acquisition at $1.27 per share. 83,312
11/19/2012 89,400 Acquisition at $1.26 per share. 112,644
11/14/2012 100,000 Acquisition at $1.21 per share. 121,000
11/14/2012 150,000 Acquisition at $1.12 per share. 168,000
11/14/2012 12,300 Acquisition at $1.13 per share. 13,899
08/06/2012 347,500 Acquisition at $1.75 per share. 608,125
08/06/2012 52,500 Acquisition at $1.75 per share. 91,875
08/09/2011 30,000 Acquisition at $5.68 per share. 170,400
08/09/2011 70,000 Acquisition at $5.81 per share. 406,700
They're all failed enterprises due to lack of leadership vision and they are the source of Nuance's current management team.
Heuston, we've got a problem here!
Agreed, any well-informed FoxNews viewer will no doubt agree. The Obama Gestapo communist administration never stops trying to get its own people killed needlessly. Makes perfect sense!
Revs seem to have stabilized and growing at a steady, albeit not terribly exciting, pace. Still growth is growth and combined with more diversified profits and a solid dividend payout, CCUR has a ways to run from a pps perspective. It's looking more like high-yielding bond with an attached lottery ticket than a risky tech play.
For me, the best part of the call:- "[No Q&A session for this event]" and no chance to cast a pessimistic outlook on the future.
Wonderful but why not cut costs even more and deploy a text-to-speech program to handle the entire call?
Just kidding, good job management.
NCE relates to the chemical originality of the drug (New Chemical Element). It has nothing to do with the target population. NCE designation bestows 5 years exclusivity. Amarin just got 3 years and half of that has already expired. Such is the 'efficiency' of the FDA.
"The whole deal is worth much more"
Or, if they don't defeat Parkinsons, a lot less. The potential $600M milestone payments will only be paid in full in the event the drug succeeds in phase 1, phase 2 and phase 3 trials and is them commercialized. That's not exactly a given now is it? How would you discount the future value of this potential cash flow? Realistically the current value there is likely around 12 to 15% at best, given drug failure rates and could be worse here given that nobody has ever found anything effective against this disease.
It's time to dump IKAN. Why screw around trying to improve copper-based bandwidth if wireless fiber (DIDO) works? Before responding, please google Steve Perlman pCell. It sounds too good to be true except Perlman has a well-documented history for inventing the impossible.
Why not take a peek at the bio's of management:-
"..Previously, Paul (Ricci) spent nearly a decade at Xerox Corporation, where he served as president of the desktop system division and a corporate vice president. .."
"Tom Beaudoin is responsible for the company’s worldwide financial analysis and administrative operations. Tom joined Nuance in July 2008 from Polaroid Corporation where he was president, CFO, and COO."
"Bruce Bowden joined Nuance in 2010 to drive company-wide strategy and lead efforts to grow the business through acquisitions and business relationships. Bruce came to Nuance from Nokia, "
But don't mention the terms of the actual SPA that was rescinded.
Time to test the FDA's decision in the courts methinks.
Ooops, forgot the statement:-
"Amarin is reviewing the FDA's reasoning for granting Vascepa three-year, rather than five-year, exclusivity, and evaluating whether to challenge the decision," stated John Thero, President and Chief Executive Officer of Amarin. "Over the past year, Amarin has significantly bolstered its patent position for Vascepa thereby decreasing the relative value of FDA marketing exclusivity in protecting Vascepa. Amarin now has 40 issued and allowed U.S. patents that provide the primary means to protect the exclusivity of Vascepa to 2030. These patents, all but two of which expire in 2030, are anticipated to protect the exclusivity of Vascepa well beyond the FDA marketing exclusivity period and to augment the protection afforded by Amarin's trade secrets and existing manufacturing barriers to entry."
yes I know. After five losing tails, one would have thought the coin might have turned up heads but it was not to be. Amarin remains an acursed entity it would appear!
Leerink raised its price target for Neurocrine shares to $23 from $18 citing positive feedback on the company's KINECT-2 data. The firm reiterates an Outperform rating on the stock.
If just 2 engineers can leave Yahoo and create $19B value in just a couple of years, one is left scratching one's head as to the reason that the thousands of engineers who remained cannot create any value at Yahoo. Surely the key failure at Yahoo must therefore be management!